ICCS 2020 - Sponsors & Organizers
Sponsors
DNB is Norway's largest financial services group and one of the largest in the Nordic region in terms of market capitalization. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. Within DNB’s international strategy, healthcare is a prioritized area.
DNB is the Nordic Healthcare Bank and a top ranking healthcare bank in the U.S. The clients are serviced by bankers and industry experts located in New York, Oslo and Stockholm. The company assists international pharma clients with business development by actively monitoring the Nordic early-stage companies for promising technologies/products |
Precision for Medicine, Oncology and Rare Disease is the first comprehensive, fully integrated CRO devoted to oncology and rare disease combining this unique experience with Omics, big data + biomarker-guided drug development.
Precision’s uniquely integrated offering enables the science of precision medicine by combining novel clinical trial designs, industry-leading operational and medical experts, advanced biomarker solutions, and an unequivocal passion for rare diseases and oncology. Precision provides an uncommon array of talent and services to enable our pharmaceutical and life sciences clients to access new advancements, stay ahead of regulatory changes and ultimately achieve their goals faster. The result: a tailored pathway to approval for oncology and rare disease innovators. |
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Takeda's passion and pursuit of potentially life-changing treatments for patients is deeply rooted in its distinguished history in Japan since in 1781.
|
Organizers
North America
Mass Medical Angels (MA2) is a seed stage investor group exclusively focused on life science and healthcare investments. Our mission is to bring more clinical tools to the marketplace, while attaining superior returns for our investors. To do this, we provide financing and mentoring to early-stage life-science companies so that they can obtain further funding, reach positive cash-flows or get acquired. MA2 members are carefully vetted for their deep expertise around the health sciences. Many of them have been researchers, clinicians, venture capitalists, executives, consultants, engineers, bankers or attorneys. They bring a willingness to support early stage companies to further our mission. In addition, we draw on our deep relationships with the institutions in Boston healthcare supercluster, the leading healthcare innovation center in the world. They provide additional resources, including deal flow, expertise and advisors for the companies we work with. www.massmedangels.com
|
Quebec
The Oncopole brings together various stakeholders to work on structuring projects. This partnership is a unique co‑creation with an inclusive idea development and implementation process which involved over 50 experts from the scientific community collaborating over the past year to identify its priorities. Recognizing the range of resources and infrastructures currently available as well as the strategic positioning of many researchers here in Québec, this project will strengthen, to the patient's benefit, the research and innovation ecosystem.
The Oncopole mobilizes the community around a shared vision:
Philadelphia
|
The Wistar Institute is the nation’s first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research.
In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools. www.wistar.org |
Europe
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatment. Organized as national non-profit member organization, the nearly 100 members represent the entire value chain including academic research institutes, university hospitals, start-ups, biotech and international Pharma companies. The cluster is advancing a growing pipeline of preclinical and clinical stage assets with strength in cancer immunotherapy and precision medicine. www.oslocancercluster.no
|
OBN is the UK’s largest and most innovative not-for-profit R&D membership organisation for Life Sciences with over 400-member companies, ranging from start-ups through to unicorns and Big Pharma, and is the most national of all the UK membership groups. www.obn.org.uk
Our goal is to create and develop an environment that nurtures the emergence and growth of innovative and successful Life Sciences companies and new products / services by providing unrivalled opportunities for networking, partnering, purchasing, training, advising and advocacy activities. OBN’s four distinct and differentiated flagship events (BioTrinity, BioForward BioSeed, & OBN Awards) are a series of major events where each satisfies a specific need but together address all the various & critical requirements of the life sciences sector. |
Biopôle Lausanne is a life sciences campus hosting a vibrant community of world-renowned industry players and research institutes, based in Lausanne (Switzerland), at the heart of the Swiss Health Valley. It offers a world-class combination of modern infrastructure (up to 134,000 sqm/1,440,000 sqft of office and laboratory space), added value services, a dense network and unparalleled community engagement where members can thrive and bring science to life. Today, Biopôle houses more than 100 companies and organizations, 25 world-famous research groups, a life science incubator (StartLab) and a Digital Health Hub, enabling outstanding innovation for the betterment of healthcare. www.biopole.ch
|
Matwin is a French open-innovation platform strictly dedicated to the support of innovation in oncology. Our main goal is to select R&D innovative projects (headed by French or European academic teams or start-ups) with high transfer potential in oncology and to support them through an accelerator programme in the development and closing of early-stage partnerships (with industrial partners or investors). The programme is supported by an ongoing partnership with major international companies involved in oncology: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Exact Sciences, GlaxoSmithKline, Janssen, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche & Sanofi.
On top of our support to project leaders, MATWIN organises each year a European Partnering convention so called MEET2WIN fully dedicated to open innovation in oncology. Each year the convention brings together nearly 300 european participants (international companies, biotechs, start-ups, researchers, investors, TTO, etc.) and generates more than 1,000 B2B meetings to increase collaboration opportunities in the fight against cancer. www.matwin.fr |